The Preclinical Pharmacology Core offers a variety of drug development services to investigators at UT Southwestern as well as external academic clients. The Core was established in 2007 by the Biochemistry Department through the auspices of a program project grant in cancer (NCI PO1 CA095471) and has since expanded to support additional grant-funded research activities as well as fee-for-service projects.
The Preclinical Pharmacology Core has established assays to evaluate in vitro drug toxicity and specificity against a wide-panel of tumor cell lines, in vitro drug stability using hepatocytes, microsomes, and S9 fractions, drug solubility and formulation for in vivo work, plasma protein binding, and inhibition of cytochrome p450 drug metabolizing enzymes. The Core additionally has experience in administration of novel compounds by various routes (IV, IP, PO, SC) to evaluate both in vivo toxicology and drug pharmacokinetics and when requested to help with studies to evaluate drug efficacy in a variety of models. Finally, the Core has established relationships with several pharmacology contract research organizations for evaluation of off-target interactions of more advanced compounds such as hERG binding and genotoxicity. Assistance with study design, implementation and analysis are provided. Core resources can be accessed on a fee-for-service basis or in a collaborative grant-funded situation. Assistance with grant writing is available. New projects require consultation with the Core director prior to initiation.
The lab is affiliated with UT Southwestern’s Department of Biochemistry and is supported by grants from the National Institutes of Health and the Cancer Prevention and Research Institute of Texas.